Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aurinia Pharmaceuticals Inc AUPH

Healthcare Biotechnology
Aurinia Pharmaceuticals Inc. is a Canada-based fully integrated biopharmaceutical company. The Company is focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. The Company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis... see more

Recent & Breaking News (NDAQ:AUPH)

AUPH Equity Alert: ROSEN, Top Ranked Investor Counsel, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Inquire About Securities Class Action Investigation - AUPH

Newsfile March 23, 2022

AUPH INVESTOR NOTICE: ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Inquire About Securities Class Action Investigation - AUPH

Newsfile March 21, 2022

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

Business Wire March 16, 2022

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aurinia Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation - AUPH

PR Newswire March 15, 2022

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

Business Wire March 15, 2022

AUPH Investor Alert: ROSEN, A Top Ranked Law Firm, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses Exceeding $100K to Inquire About Securities Class Action Investigation - AUPH

Newsfile March 13, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aurinia Pharmaceuticals Inc. - AUPH

PR Newswire March 9, 2022

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Inquire About Securities Class Action Investigation - AUPH

Business Wire March 7, 2022

Aurinia Pharmaceuticals to Present at Upcoming Investor Conferences

Business Wire March 3, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aurinia Pharmaceuticals Inc. - AUPH

PR Newswire March 2, 2022

Aurinia Reports Fourth Quarter and Full Year 2021 Financial Results and Company Updates

Business Wire February 28, 2022

Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2021 Financial Results on February 28, 2021

Business Wire February 9, 2022

Aurinia Pharmaceuticals to Present at the 11th Annual Leerink Global Healthcare Conference

Business Wire February 3, 2022

Aurinia Pharmaceuticals to Present at Upcoming January Investor Conferences

Business Wire January 4, 2022

Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS(TM) (voclosporin) for the Treatment of Adults With Active Lupus Nephritis (LN)

Business Wire December 9, 2021

Aurinia Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference

Business Wire November 10, 2021

Aurinia Reports Third Quarter and Nine Months 2021 Financial Results and Company Updates

Business Wire November 3, 2021

Aurinia Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis

Business Wire November 1, 2021

Aurinia Pharmaceuticals to Release Third Quarter 2021 Financial Results on November 3, 2021

Business Wire October 27, 2021

Aurinia Pharmaceuticals to Present Five Abstracts at ASN Kidney Week 2021 and ACR Convergence 2021

Business Wire October 26, 2021